Grand River Aseptic Manufacturing (GRAM), a sterile injectable contract development and manufacturing organization (CDMO) specializing in biologics, small molecules and vaccines, is investing $50 million to continues its growth in Grand Rapids, MI.
 
This latest expansion is the third multi-million-dollar investment in the past two years and increases the footprint of GRAM’s large-scale fill/finish facility by 18,000 sq. ft., bringing the total square footage across all facilities to 230,000 sq. ft. The phase I expansion of this facility opened in June 2020 and was recognized by the International Society for Pharmaceutical Engineering (ISPE) as the 2021 Facility of the Year Award Winner for Special Recognition for Operational Agility: COVID-19 Impact.
 
“Embarking on multiple expansions and opening the doors of two state-of-the-art pharmaceutical manufacturing facilities over the last two years, right here in our hometown, is tremendous,” said Tom Ross, president and CEO of Grand River Aseptic Manufacturing. “The innovative modular technology GRAM ordered for this new space arrives in early 2022 and allows GRAM to expand offerings to existing and future customers, ultimately taking on more products to support industry demand for getting products to market.”
 
The existing large-scale fill/finish facility utilizes world-class equipment and technology from the likes of Bausch+Ströbel, SKAN, and IMA. The phase II expansion includes a new VarioSys syringe and vial filler, and an additional Bausch+Ströbel Vial Filler with SKAN Isolator Technology (a duplicate of the current vial filler to increase manufacturing capacity). Expanding their portfolio with advanced, flexible modular technology sets GRAM apart to biotech and pharmaceutical companies interested in efficient scale-up of products.